Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Promacta eltrombopag: Phase II data

In a double-blind, placebo-controlled Phase II trial (TRA100773) in 118 patients, the 2 highest doses of eltrombopag met the primary

Read the full 200 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE